An encephalitogenic peptide
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PLP (139-151) (trifluoroacetate salt)

Item No. 33159

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-histidyl-L-seryl-L-leucylglycyl-L-lysyl-L-tryptophyl-L-leucylglycyl-L-histidyl-L-prolyl-L-α-aspartyl-L-lysyl-L-phenylalanine, trifluoroacetate salt
Synonyms
  • linPLP
  • Proteolipid Peptide (139-151)
Molecular Formula
C72H104N20O17 • XCF3COOH
Formula Weight
1521.7
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
Water: soluble
SMILES
N[C@@H](CC1=CN=CN1)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(NCC(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CC(C)C)C(NCC(N[C@@H](CC2=CN=CN2)C(N3[C@H](C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC4=CC=CC=C4)C(O)=O)=O)=O)=O)CCC3)=O)=O)=O)=O)CC5=CNC6=CC=CC=C56)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C72H104N20O17.C2HF3O2/c1-40(2)25-51(63(99)80-36-60(95)84-55(30-45-34-77-39-82-45)71(107)92-24-14-21-58(92)70(106)89-54(31-61(96)97)68(104)85-50(20-11-13-23-74)66(102)90-56(72(108)109)27-42-15-6-5-7-16-42)86-67(103)53(28-43-32-78-48-18-9-8-17-46(43)48)88-65(101)49(19-10-12-22-73)83-59(94)35-79-64(100)52(26-41(3)4)87-69(105)57(37-93)91-62(98)47(75)29-44-33-76-38-81-44;3-2(4,5)1(6)7/h5-9,15-18,32-34,38-41,47,49-58,78,93H,10-14,19-31,35-37,73-75H2,1-4H3,(H,76,81)(H,77,82)(H,79,100)(H,80,99)(H,83,94)(H,84,95)(H,85,104)(H,86,103)(H,87,105)(H,88,101)(H,89,106)(H,90,102)(H,91,98)(H,96,97)(H,108,109);(H,6,7)/t47-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-;/m0./s1
InChi Key
XUIHONJLEQCVEQ-OVFYYFFASA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $36

    Add

    5 mg

    $145

    Add

    10 mg

    $253

    Add

    25 mg

    $502

    Add
    Product Description

    PLP (139-151) is an encephalitogenic peptide fragment of myelin proteolipid protein (PLP).1 In vivo, PLP (139-151) (150 µg/animal) induces the formation of inflammatory foci, axonal injury, and demyelination in the spinal cord, as well as motor deficits in mice. It is commonly used to induce experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS), in mice.1,2,3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lourbopoulos, A., Matsoukas, M.-T., Katsara, M., et al. Cyclization of PLP139-151 peptide reduces its encephalitogenic potential in experimental autoimmune encephalomyelitis. Bioorg. Med. Chem. 26(9), 2221-2228 (2018).

    2. Reddy, J., Bettelli, E., Nicholson, L., et al. Detection of autoreactive myelin proteolipid protein 139-151-specific T cells by using MHC II (IAs) tetramers. J. Immunol. 170(2), 870-877 (2003).

    3. Mohindru, M., Kang, B., and Kim, B.S. Functional maturation of proteolipid protein139-151-specific Th1 cells in the central nervous system in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 155(1-2), 127-135 (2004).